Titan Pharma Forays into Merger Agreement with KE Sdn. Bhd.

Titan Pharmaceuticals, Inc. has revealed that it is engaged in a Merger and Contribution and Share Exchange Agreement for a business merger with KE Sdn. Berhad. The board of directors of Titan approved the Merger Agreement. If Titan's and KE's stockholders approve the Merger Agreement and the transactions outlined in the agreement are completed, Titan will merge with KE in a "reverse merger" involving two steps.

TTNP Merger Sub, Inc, a company based in Delaware and a fully owned subsidiary of BSKE Ltd, an exempted company in Cayman Islands, will merge with and into Titan; the separate entity of Merger Sub will end; and Titan will become the surviving company of the merger and a direct fully owned subsidiary of BSKE.

Within five days of Titan and BSKE submitting a proxy statement/prospectus for the planned transaction, KE shareholders have the option to participate in a share exchange agreement with biopharmaceutical company and BSKE. This agreement will involve exchanging all KE shares for BSKE ordinary shares immediately after the Merger. Titan has the right to cancel the Merger Agreement if not all KE shareholders participate in the Share Exchange Agreement within the given timeframe.